User login
Key clinical point: Findings from this phase 2 trial support feasibility and safety of perioperative systemic therapy in patients with resectable colorectal peritoneal metastases (CPM).
Major finding: The proportion of patients undergoing macroscopic complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC; risk ratio, 1.04; P = .74) and with Clavien-Dindo grade 3 or higher postoperative morbidity (risk ratio, 0.65; P = .25) was not significantly different between the perioperative systemic therapy and CRS-HIPEC alone arms.
Study details: Findings are from CAIRO6, a phase 2-superiority trial that included 79 patients with resectable CPM who were randomly allocated to either perioperative systemic therapy or CRS-HIPEC alone.
Disclosures: The study was funded by the Dutch Cancer Society and F. Hoffmann-La Roche. Dr. Koopman, Dr. Punt, Dr. Tanis, and Dr. de Hingh reported serving as a paid advisor and/or receiving grants from various sources. No other disclosures were reported.
Source: KP Rovers et al. JAMA Surg. 2021 May 19. doi: 10.1001/jamasurg.2021.1642.
Key clinical point: Findings from this phase 2 trial support feasibility and safety of perioperative systemic therapy in patients with resectable colorectal peritoneal metastases (CPM).
Major finding: The proportion of patients undergoing macroscopic complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC; risk ratio, 1.04; P = .74) and with Clavien-Dindo grade 3 or higher postoperative morbidity (risk ratio, 0.65; P = .25) was not significantly different between the perioperative systemic therapy and CRS-HIPEC alone arms.
Study details: Findings are from CAIRO6, a phase 2-superiority trial that included 79 patients with resectable CPM who were randomly allocated to either perioperative systemic therapy or CRS-HIPEC alone.
Disclosures: The study was funded by the Dutch Cancer Society and F. Hoffmann-La Roche. Dr. Koopman, Dr. Punt, Dr. Tanis, and Dr. de Hingh reported serving as a paid advisor and/or receiving grants from various sources. No other disclosures were reported.
Source: KP Rovers et al. JAMA Surg. 2021 May 19. doi: 10.1001/jamasurg.2021.1642.
Key clinical point: Findings from this phase 2 trial support feasibility and safety of perioperative systemic therapy in patients with resectable colorectal peritoneal metastases (CPM).
Major finding: The proportion of patients undergoing macroscopic complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC; risk ratio, 1.04; P = .74) and with Clavien-Dindo grade 3 or higher postoperative morbidity (risk ratio, 0.65; P = .25) was not significantly different between the perioperative systemic therapy and CRS-HIPEC alone arms.
Study details: Findings are from CAIRO6, a phase 2-superiority trial that included 79 patients with resectable CPM who were randomly allocated to either perioperative systemic therapy or CRS-HIPEC alone.
Disclosures: The study was funded by the Dutch Cancer Society and F. Hoffmann-La Roche. Dr. Koopman, Dr. Punt, Dr. Tanis, and Dr. de Hingh reported serving as a paid advisor and/or receiving grants from various sources. No other disclosures were reported.
Source: KP Rovers et al. JAMA Surg. 2021 May 19. doi: 10.1001/jamasurg.2021.1642.